Skip to content


Want to stay updated on the latest pathogen inactivation news?
You can receive our highlights by subscribing to our newsletter.


Bacterial contamination of platelet components, passive vs. active, surveillance, testing and pathogen reduction technologies

Dr. Richard J. Benjamin, MBChB, PhD, FRCPath
Cerus Corporation,
Concord, California, USA




Safety surveillance and the introduction of pathogen reduced platelets: the role of national hemovigilance systems in the Cerus post-market clinical follow-up strategy

Dr. John Pitman, PhD
Cerus Corporation
Concord, USA



Overview of the variability in platelet production processes and applied safety measures

Dr. Mohammad R. Abedi, PhD
Örebro University Hospital
Örebro, Sweden


The information on this site is not country-specific, and may contain information that is outside the approved indications for the country in which you are located.
Use of INTERCEPT Plasma or Platelets is contraindicated in patients with a history or allergic response to amotosalen or psoralens. Consult instructions for use for indications, contraindications, warnings, and precautions.

Cerus, INTERCEPT and the Cerus logo are trademarks of Cerus Corporation.

© 2023 Cerus Corporation. All Rights Reserved. MKT-EN 000157, v43.0